Volume 115, Issue 4, Pages (October 1998)

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

Celiac disease–like abnormalities in a subgroup of patients with irritable bowel syndrome Ulrich Wahnschaffe, R. Ullrich, E.O. Riecken, J.D. Schulzke Gastroenterology.

Overview and pathogenesis of celiac disease Martin F. Kagnoff Gastroenterology Volume 128, Issue 4, Pages S10-S18 (April 2005) DOI: /j.gastro

Celiac Disease Genetics: Current Concepts and Practical Applications Ludvig M. Sollid, Benedicte A. Lie Clinical Gastroenterology and Hepatology Volume.

Serum immunoglobulin a from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation Tuula Halttunen, Markku Mäki.

Interleukin 15 mediates epithelial changes in celiac disease Luigi Maiuri, Carolina Ciacci, Salvatore Auricchio, Virginia Brown, Sonia Quaratino, Marco.

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease Richard N. Fedorak, *, Alfred Gangl, ‡, Charles.

Imaging of perianal Crohn's disease S. Ardizzone, G. Maconi, A. Cassinotti, A. Massari, G. Bianchi Porro Digestive and Liver Disease Volume 39, Issue 10,

Volume 32, Issue 1, Pages (July 1957)

Masatoshi Kudo Clinical Gastroenterology and Hepatology

It's time to bring the best and brightest back to gastroenterology!

Bipolar treatment efficacy

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease Erik J. Schoon, Simona Bollani, Peter.

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: A dose-finding study with newly developed mesalamine Wolfgang Kruis, Simon Bar–Meir,

Hisashi Moriguchi, Makoto Kobayashi, Raymond T. Chung, Chifumi Sato

Diagnosis of celiac sprue

Leptin, obesity, and liver disease

Andrew V. Thillainayagam, John B. Hunt, Michael J.G. Farthing

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease Erik J. Schoon, Simona Bollani, Peter.

Genetics and Genomics in the Practice of Medicine

Polyxeni Koutkia, Zhiren Lu, Tai C. Chen, Michael F. Holick

Volume 128, Issue 4, Pages (April 2005)

Volume 124, Issue 4, Pages (April 2003)

Risks and Benefits of Infliximab for the Treatment of Crohn’s Disease

Chest pain in achalasia: Patient characteristics and clinical course

Appendectomy is followed by increased risk of Crohn's disease

Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double- blind, placebo-controlled trials Stephen B Hanauer, Ulf Strömberg

Volume 115, Issue 1, Pages (July 1998)

Antje Timmer*, Lloyd R. Sutherland*,‡, Francois Martin§

Volume 130, Issue 2, Pages (February 2006)

A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn's Disease Refractory to Biologic Therapy Geoffrey M. Forbes, Marian J. Sturm,

Volume 26, Issue 2, Pages (February 2018)

Lip edema Journal of the American Academy of Dermatology

Volume 120, Issue 4, Pages (March 2001)

Severe Constipation Clinical Gastroenterology and Hepatology

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

Volume 119, Issue 6, Pages (December 2000)

Prednisolone and Budesonide for Short- and Long-Term Treatment of Microscopic Colitis: Systematic Review and Meta-analysis Michael J. Stewart, Cynthia.

Lise L. Kjaergard, Sarah L. Frederiksen, Christian Gluud

AGA technical review on nonalcoholic fatty liver disease

Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease Gerassimos J.

Volume 4, Issue 5, Pages 2-3 (October 2006)

Volume 121, Issue 5, Pages (November 2001)

Volume 150, Issue 7, Pages (June 2016)

Volume 17, Issue 2, Pages (February 1950)

Diagnostic Colonoscopy: The End Is Coming

Volume 119, Issue 4, Pages (October 2000)

AGA technical review on osteoporosis in gastrointestinal diseases

Volume 117, Issue 4, Pages (October 1999)

Volume 117, Issue 3, Pages (September 1999)

Mesalamine and relapse prevention in Crohn's disease

Michelle Maria Pietzak Gastroenterology

Christopher Hung, Desmond Leddin

Capsule Endoscopy for Refractory Iron Deficiency Anemia in Crohn’s Disease: Captivating Pathology, Hybrid Therapy Long Le, Brian M. Fung, James H. Tabibian

This Month in AJKD American Journal of Kidney Diseases

Masatoshi Kudo Clinical Gastroenterology and Hepatology

Physical Function in Patients with Cancer

Volume 121, Issue 4, Pages (October 2001)

Scott K. Fung, Anna S.F. Lok Clinical Gastroenterology and Hepatology

Hisashi Moriguchi, Makoto Kobayashi, Raymond T. Chung, Chifumi Sato

Hepatic oxygen supplementation as therapy in cirrhotic liver disease

Matthew J. Lee, Claire E. Parker, Sarah R

Predictors of response to infliximab in patients with Crohn's disease

Volume 163, Issue 2, (October 2015)

Medical Therapy for Refractory Pediatric Crohn’s Disease

Assessing activity of pediatric Crohn's disease: Which index to use?

This Month in AJKD American Journal of Kidney Diseases

Distinguishing Patient Satisfaction With Treatment Delivery From Treatment Effect: A Preliminary Investigation of Patient Satisfaction With Symptoms After.

Volume 157, Issue 4, Pages e6 (October 2019)

Jordan E. Axelrad, Simon Lichtiger, Amrita Sethi

Presentation transcript:

Volume 115, Issue 4, Pages 835-840 (October 1998) Budesonide versus prednisone in the treatment of active Crohn's disease Simon Bar–Meir*, Yehuda Chowers*, Alexandra Lavy‡, Dov Abramovitch§, Amos Sternberg∥, Georges Leichtmann¶, Ron Reshef#, Shmuel Odes**, Menachem Moshkovitz‡‡, Raphael Bruck§§, Rami Eliakim∥∥, Eran Maoz¶¶, Ulrich Mittmann## Gastroenterology Volume 115, Issue 4, Pages 835-840 (October 1998) DOI: 10.1016/S0016-5085(98)70254-9 Copyright © 1998 American Gastroenterological Association Terms and Conditions

Fig. 1 Efficacy results and steroid side effects with PRED and BUD therapy. *P = 0.006, 90% confidence interval (two-sided). Difference in response rate, 1.48%; lower limit, −13.07; upper limit, 10.12; P = 0.8881. Gastroenterology 1998 115, 835-840DOI: (10.1016/S0016-5085(98)70254-9) Copyright © 1998 American Gastroenterological Association Terms and Conditions

Fig. 2 CDAI values during each visit in the PRED-treated (▴) and BUD-treated (2) groups. For 90% confidence interval, P = 0.8881; two-sided Fisher exact test. Gastroenterology 1998 115, 835-840DOI: (10.1016/S0016-5085(98)70254-9) Copyright © 1998 American Gastroenterological Association Terms and Conditions